Aims: The aims of the study were to evaluate the multidrug resistance profile and mechanisms of carbapenem resistance in Pseudomonas aeruginosa clinical isolates using phenotypic and genotypic methods. Nmema et al.; JAMMR, 29(9): 1-8, 2019; Article no.JAMMR.48650 2 Teaching Hospital, and susceptibilities to imipenem (10 µg), meropenem (10 µg) and a panel of antibiotics were performed by the disk diffusion method. Genotypic methods including Polymerase Chain Reactions (PCR) and agarose gel electrophoresis were carried out according to established protocols. oprD and bla IMP gene primers were used for the PCR amplification. Results: Fifty percent (50%) of the isolates showed multiple drug resistance. Four isolates (40%) were carbapenem resistant (CR). oprD gene was detectedin 90% (9/10) of the isolates. 75% (3/4) of CR strains were among the strains showing oprD gene. 25% (1/4) CR strain (PA1421) was oprD negative. Loss or mutation of oprD gene seems to be the mechanism of carbapenem resistance in strain PA1421. Conclusion: Loss or mutation of oprD gene was identified in this study as a mechanism of carbapenem resistance. oprD gene encodes the outer membrane protein (OprD) porin in P. aeruginosa whose deficiency confers resistance to carbapenems, especially imipenem. Surveillance of the antimicrobial susceptibility patterns of P. aeruginosa is of critical importance in understanding new and emerging resistance trends, reviewing antibiotic policies and informing therapeutic options.
INTRODUCTION
The World Health Organization (WHO) in 2017 released a global priority pathogens list (global PPL) of antibiotic-resistant bacteria to help in prioritizing the research and development of new and effective antibiotic treatments. The list contains three categories of antibiotic-resistant pathogenic bacteria categorized as Priority 1 (Critical), Priority 2 (High), and Priority 3 (Medium). Carbapenem-resistant Pseudomonas aeruginosa rank second in the critical list which includes multidrug resistant bacteria that pose a particular threat in hospitals, nursing homes, and among patients whose care requires devices such as ventilators and blood catheters, causing severe and often life threatening infections such as bloodstream infections and pneumonia [1] .
Carbapenems, such as imipenem and meropenem are often used as last resort antibiotics for the treatment of multidrug resistant Pseudomonas aeruginosa infections [2] . Of all the beta-lactams, carbapenems possess the broadest spectrum of activity and the greatest potency against bacteria, and so are often reserved for more severe infections or used as 'last-line' agents.
Like all beta-lactams, carbapenems inhibit bacterial cell wall synthesis by binding to the penicillin-binding proteins and interfering with cell wall formation. Carbapenems have excellent activity against a broad spectrum of aerobic and anaerobic bacteria, and are notable for their ability to inhibit beta-lactamase enzymes. They are usually employed in serious infections such as intra-abdominal, skin and soft tissue that are resistant to first line antibiotics [3] .
Pseudomonas aeruginosa is an opportunistic pathogen associated with a range of healthcare associated infections that can be particularly severe in immunocompromised patients, and is extraordinary because it has the potential to overcome the activity of almost all the available antibiotics [4] , and the ability to acquire genes encoding resistance determinants. The development of carbapenem resistance among P. aeruginosa strains has been attributed to multiple factors such as plasmid or integronmediated carbapenemases, increased expression of efflux systems, reduced porin expression and increased chromosomal cephalosporinase activity [3] . The main reported mechanism of resistance to carbapenems involves the loss or downregulation of OprD porin from the outer membrane through deletions, mutations or insertions in the oprD gene [5] .
The increasing isolation in healthcare settings of P. aeruginosa strains resistant to carbapenems has raised a global alarm which necessitates constant surveillance and more detailed research. In the present study, the authors used phenotypic tests and molecular techniques to identify the resistance determinants in carbapenem-resistant P. aeruginosa isolated from hospital patients.
MATERIALS AND METHODS

Sampling
Ten (10) 
Antimicrobial Susceptibility Testing
Susceptibilities of the isolates to imipenem (10 μg), meropenem (10 μg), colistin sulphate (10 µg), ofloxacin (5 µg), gentamicin (10 µg), and ceftazidime (30 µg) (Oxoid Ltd, Cambridge, UK.) were determined according to Clinical and Laboratory Standard Institute guidelines [6] . A pure culture of each P. aeruginosa isolate was used. Four to five colonies of each isolate were transferred to 5 mL of nutrient broth and were cultured overnight at 35°C. The overnight cultures were then diluted with sterile saline (0.85% NaCl) in Bijou bottles, and their turbidity was adjusted to 0.5 McFarland standards. The inocula were spread with a sterile cotton wool swab on Mueller-Hinton agar. The antibiotic sensitivity disks were applied with sterile forceps, and the agar plates were incubated for a full 24 h at 35°C aerobically. The inhibition zone diameter (ZD) for each isolate was measured and interpreted as "Resistant", "Intermediate" or "Sensitive" using a standardized table according to CLSI breakpoints [6].
DNA Extraction
Deoxyribonucleic acid (DNA) extraction from each P. aeruginosa isolate was carried out by modification of the simple crude extraction methods previously described for Salmonella enterica [7] and Streptococcus pneumonia [8] . Twenty-four-hour-old pure colonies of each P. aeruginosa isolate were suspended in 500 μL of Tris-buffer (1x) in appropriately labelled Eppendorf tubes (Eppendorf North America, Hauppauge, NY, USA). The cells were washed three times in sterile distilled water while vortexing and centrifuging at 10, 000 rpm. Tubes were covered and sealed with paraffin tape to prevent accidental opening. After the last washing, the suspensions were boiled for 10 min in a water-bath at 100°C and then cold shocked in ice for 2 min. Thereafter, they were centrifuged at 14000 rpm for 5 min to obtain the supernatant. The supernatants containing the DNA were stored at 4°C before use. Aliquots of 2 µL of template DNA were used for PCR.
Polymerase Chain Reactions (PCR)
Primers and deoxynucleases (dNTPs)
Outer membrane protein D gene primer (oprD F and oprD R); and imipenemase gene primer 
Preparation of mastermix for amplification of oprD gene
The Mastermix for amplification of oprD gene was constituted by using a microliter pipette to add the required reagents into an Eppendorf tube ( Table 1 ). The reagents were mixed to obtain a uniform mixture using a vortex mixer and centrifuge. The same procedure was used to prepare a separate Mastermix for the amplification of bla IMP gene. 
Protocols for PCR
Eighteen microliters (18 µL) of the Mastermix was introduced into each of the PCR tubes and 2 µL of DNA was added. The PCR tubes were loaded into a thermal cycler (Prime) and subjected to the following conditions for the different primers as previously described [9-12].
The oprD gene was amplified with the following primers:
Product= 1329bp (Accession nos. KT736319/KT728193/MH135304) PCR conditions were: 1 cycle of initial denaturation at 94°C for 2 min; 30 cycles of (denaturation at 94°C for 45 sec, annealing at 55°C for 45 sec, elongation at 72°C for 45 sec); and final elongation for 72°C for 5 min. Expected size of amplicon 1329-bp. -TGA GCA AGT TAT CTG TAT  TC-3'   bla   IMP -1R 5'-TTA GTT GCT TGG TTT TGA  TG-3' PCR conditions were: 1 cycle of initial denaturation at 94°C for 2 mins; 30 cycles of (denaturation at 94°C for 1 min, annealing at 56°C for 1 min, elongation at 72°C for 2 min); and final elongation at 72°C for 10 min. Expected size of amplicon 749-bp.
Agarose Gel Electrophoresis
At the completion of the amplification, PCR products were resolved on l% agarose gel prepared by dissolving 1 g of agarose powder in 100 ml of 1x Tris-borate-EDTA (TBE) buffer solution inside a clean conical flask. The 1% agarose solution was heated in a microwave oven for 2-3 minutes and was observed for clarity which was an indication of complete dissolution. The mixture was then allowed to cool to about 50°C after which 0.5 µl of 1 μg/mL ethidium bromide (Sigma-Aldrich, St Louis, MO, USA) was added. It was allowed to cool further and then poured into a tray sealed at both ends with support to form a mould with special combs placed in it to create wells. The comb was carefully removed after the gel had set and the plate was placed inside the electrophoresis tank which contained 1x TBE solution. A 5 µl of amplicon was mixed with 5 µl of Orange G (loading buffer) and loaded to the well of the agarose gel. The power supply was adjusted to 100 volts for 25 minutes. For each run, a 100 base-pair molecule weight DNA standard (size marker) was used to determine the size of each PCR product. The DNA bands were then visualized with a short wave ultraviolet transilluminator and photographed using gene gel bioimaging system (SynGene Bioimaging System; Syngene UK, Cambridge, UK). The PCR product was then analyzed.
Data Analysis
Data obtained in the study was analyzed using the following equations where 'A' is antibiotic tested; 'CS' means carbapenem-susceptible; 'CR' means carbapenem-resistant:
Percentage resistance to antibiotic A = (number of isolates resistant to A / total number of isolates) ×100
(1)
Percentage CS isolates having OprD gene = (number of CS isolates / total number of isolates) ×100
Percentage CR isolates having OprD gene = (number of CR isolates / total number of isolates) ×100 (3)
RESULTS AND DISCUSSION
Results of Antimicrobial Susceptibility Screening
The results of antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates are presented in Table 2 . The diameters of zones of inhibition (IZD) in mm were interpreted using The results of agarose gel electrophoresis of PCR products of P. aeruginosa isolates are shown in Fig. 1 . Nine of the isolates were positive for oprD gene which showed bands corresponding to 1329 base pairs. Strain PA1421 (well 8) did not show any band corresponding to 1329 base pairs and consequently was interpreted as oprD negative. The ladder (L) is a 100 base-pair molecular weight DNA standard (size marker).
Correlation of carbapenem susceptibility, multiple drug resistance (MDR), and oprD detection
The correlation of carbapenem resistance and multiple drug resistance (A); carbapenem resistance and oprD -positive (B); carbapenem resistance and oprD -negative (C); carbapenem susceptible and oprD -positive (D) are shown in Table 3 . The findings of the present study are similar to reports of previous authors. In India, Shashikala et al. [14] reported a 10.9% resistance to imipenem and meropenem. Yin et al. [15] in China reported higher rates of resistance such as 64.3% to imipenem and 67.9% to meropenem. These findings corroborate global reports of increasing carbapenem resistance among P. aeruginosa clinical isolates.
Fifty percent (50%) of P. aeruginosa isolates were multidrug resistant (MDR). MDR is very common in P. aeruginosa isolates from hospitals and other sources and a major cause of concern in the health sector in Nigeria [16] .
All the isolates were susceptible to colistin sulphate (100%), despite poor diffusion of colistin in agar medium. This seems to agree with the current use of colistin as the 'last lineʹ antibiotic for multidrug-resistant Gram negative bacteria pathogens [17] .
Pseudomonas aeruginosa isolates showed 60% sensitivity to carbapenems in the present study. A similar report from Iraq finds imipenem the best antibiotic against MDR P. aeruginosa from clinical sources (88.4% sensitivity) and from sewage (96.7% sensitivity) [18] . These findings are in consonance with several reports that carbapenems are very useful as last resort betalactams for multiple-drug resistant P. aeruginosa infections. However, emerging resistance to carbapenems limits therapeutic options. Therefore periodic surveillance of the resistance pattern is critical for the selection of an appropriate empiric antimicrobial agent [14] .
In the PCR, oprD gene with a band size of 1329-bp was detected in nine of the isolates but was not detected in one strain PA1421 (Plate 1). Detection of oprD gene in three out of four (75%) of carbapenem resistant (CR) strains indicates the presence of outer membrane protein (OprD), an evidence that loss or mutation of oprD was not the mechanism of resistance in these strains (PA1340, PA1380, PA1656). One out of four (25%) of CR strains showed a loss or mutation of oprD known to result in carbapenem resistance and which seems to be the mechanism of carbapenem resistance in the strain (PA1421). oprD was detected in 100% (6/6) of carbapenem susceptible (CS) strains.
P. aeruginosa can use a combination of chromosomally encoded and /or plasmid encoded mechanisms to evade carbapenem therapy. Yin et al. [15] found the main mechanism associated with carbapenem resistance was mutational inactivation of oprD in 88.65% of samples.
Carbapenems enter into the periplasmic space of P. aeruginosa through the OprD outer membrane porin. The porin loss probably by a mutational event of the oprD gene leads to imipenem resistance [19] . Furthermore, in strains with oprD downregulation, reduced susceptibility to meropenem is observed while other beta-lactams are not affected [20, 21] . Diminished expression or loss of the oprD gene is rather frequent during imipenem treatment [22] .
OprD is the outer membrane protein in P. aeruginosa whose deficiency confers resistance to carbapenems, especially imipenem. Functional studies have revealed that loops 2 and 3 in the OprD protein contain the entrance and/or binding sites for imipenem. Therefore any mutation in loop 2 and/or loop 3 that causes conformation changes could result in carbapenem resistance. OprD is also a common channel for some amino acids and peptides. Because of its hypermutability and highly regulated properties, OprD is thought to be the most prevalent mechanism for carbapenem resistance in P. aeruginosa [23] . In a study in Iran by Shariati et al. [10] , PCR assay using oprD-specific primers demonstrated that 10.52% (10/95) of imipenem-resistant P. aeruginosa isolates harbored an insertion sequence (IS) element in the oprD gene which inactivates the gene. Insertional inactivation of oprD gene resulted in a reduction of carbapenem susceptibility and loss of OprD production. 
CONCLUSION
The results of this study reveal the increasing carbapenem resistance of P. aeruginosa isolates in Nigeria, similar to reports from other countries globally [14, 15, 18] . The high rate of sensitivity (100%) of the isolates to colistin sulphate is evidence that the drug is effective as a last resort drug against MDR P. aeruginosa. The findings of this study corroborate other reports that a loss or mutation of oprD is the main mechanism of carbapenem resistance, especially during imipenem treatment [20, 21, 23 ].
Healthcare-associated infections caused by multi-drug resistant P. aeruginosa are a significant cause of morbidity and mortality in hospital settings. P. aeruginosa strains harboring carbapenem resistance mechanisms limit therapeutic options because carbapenem resistance is associated with resistance to other antibiotic classes. Therefore, surveillance of the antimicrobial susceptibility patterns of P. aeruginosa is of critical importance in understanding new and emerging resistance trends, reviewing antibiotic policies and informing therapeutic options. Increasing CR in P. aeruginosa isolates from hospital patients calls for greater commitment in research and drug development.
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